Compare Baker Hughes Co (BKR) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baker Hughes Co vs State Street SPDR S&P Biotech ETF — how do they compare? Baker Hughes Co trades at $57.78 (market cap $57.32B), while State Street SPDR S&P Biotech ETF trades at $155.35. The key difference: Baker Hughes Co pays a 1.59% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Baker Hughes Co nearer its low. Which is the better fit depends on your goals.
| BKR | XBI | |
|---|---|---|
Market Cap | $57.32B | — |
Sector | Energy | Broad Market / Factor |
52-Week High | $69.67 | $164.28 |
52-Week Low | $38.68 | $85.16 |
Enterprise Value | $58.72B | — |
Dividend Yield | 1.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baker Hughes (BKR) trades at $57.66, up 0.17% today, with a bullish technical signal and strong analyst consensus. Recent earnings beats and a 66.7% buy rating from analysts, alongside a $74.09 price target, highlight positive momentum. The company secured key LNG and power infrastructure contracts, supporting growth in energy transition markets. Operating cash flow remains robust at $3.81B for 2025, though net income dipped slightly to $2.59B.
Outlook is positive driven by LNG expansion and AI-powered energy demand, but risks include oil price volatility and integration challenges from the Chart Industries acquisition. Valuation metrics like a P/E of 18.42 and ROE of 17.14% suggest reasonable pricing for growth prospects, though execution on new contracts is critical for sustained upside.
XBI trades at $155.34, down 2.32% on the day, but maintains a bullish technical outlook with strong momentum indicators. The biotech ETF has gained significant attention after a 17% monthly surge, driven by sector rotation and M&A activity. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech's strong performance amid market volatility.
The ETF offers exposure to biotech's resurgence with AI drug discovery and deal momentum as catalysts. However, high volatility and concentrated sector risk require careful position sizing. Current technical strength suggests potential for continued upside if sector momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Baker Hughes Co
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
